Background: Sepsis is the most common health problem because of which an increased proportion of health resources are consumed. Tumour Necrosis factor alpha also plays an essential role in many diseased conditions like diabetes, cancer, etc. There have been findings suggesting a high level of correlation between TNF activity and sepsis susceptibility and mortality. Thus, the present meta-analysis was carried out to assess the role of Tumour Necrosis Factor-Alpha promoter 308A/G polymorphism in sepsis and sepsis mortality. Methods: The meta-analysis was carried out using the MOOSE guidelines. A total number of 782 articles were retrieved, out of which only 45 full-text articles were eligible. Out of that, 24 were used for meta-analysis after checking the quality of articles. The meta-analysis was carried out using MedCalc Software. The comparison of TNF factor alpha 1 and 2 among patients was calculated in the two groups. The odds ratio of these studies was used to construct the forest plot. Results: Eight studies evaluated the odds of having increased TNF1 in sepsis conditions. The plot shows that the cumulative statistics are significant at a 95% confidence level and have a p-value less than 0.05. The odds of increased TNF2 in sepsis conditions among Asians is more than in the case of TNF1. The odds ratio of 0.978 indicates that the odds of increased TNF1 in sepsis conditions among Caucasians are more than in the case of TNF2. Conclusion: The meta-analysis suggests an association between the G/A allele combination of TNF-α and sepsis risk in the Asian population compared to the Caucasian Population.

Background: The use of Aspirin in the primary prevention of cardiovascular disease (CVD) is still a topic of debate, especially in patients with diabetes. The present meta-analysis aims to rule out the efficacy of Aspirin in patients with diabetes and to compare the effectiveness of Aspirin with a placebo (or no treatment) for the primary prevention of CVD and all-cause mortality events in people with diabetes. Materials and Methods: An extensive and systematic search was conducted in Medline (via PubMed), Cinahl (via Ebsco), Scopus, and Web of Sciences from 1988 to December 2020. A detailed literature search was conducted using Aspirin, cardiovascular disease (CVD), diabetes, and efficacy to identify trials of patients with diabetes who received Aspirin for primary prevention of CVD. Demographic details with the primary outcome of events and bleeding outcomes were analyzed. The risk of bias (RoB) in included studies was evaluated using the QUADAS-2 tool. Results: A total of 5 studies out of 13 were included with 23,570 diabetic patients; 11,738 allocated to Aspirin and 11,832 allocated to the placebo group. In patients with diabetes, there was no difference between Aspirin and placebo with respect to the risk of all-cause death with a confidence interval (CI) varying 0.63 to 1.17. In addition, there were no differences in the bleeding outcomes with an odds ratio of 1.4411 (CI 0.47 to 4.34). Conclusion: Aspirin has no significant risk on primary endpoints of cardiovascular events and the bleeding outcomes in diabetic patients compared to placebo. More research on the use of Aspirin alone or in combination with other antiplatelet drugs is required in patients with diabetes to supplement currently available research.